gefitinib has been researched along with carboxymethyl-beta-cyclodextrin in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (carboxymethyl-beta-cyclodextrin) | Trials (carboxymethyl-beta-cyclodextrin) | Recent Studies (post-2010) (carboxymethyl-beta-cyclodextrin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 81 | 0 | 52 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, W; Feng, B; Li, H; Liu, L; Liu, M; Shi, Y; Su, C; Su, R; Zhao, L | 1 |
1 other study(ies) available for gefitinib and carboxymethyl-beta-cyclodextrin
| Article | Year |
|---|---|
Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Autophagy; beta-Cyclodextrins; Cell Survival; Drug Delivery Systems; Folate Receptors, GPI-Anchored; Folic Acid; Gefitinib; HeLa Cells; Humans; Molecular Targeted Therapy; Nanoparticles; Quinazolines; Serum Albumin, Bovine; Spectroscopy, Fourier Transform Infrared | 2014 |